Quarterly Results of Operations (unaudited)

12 Months Ended

Dec. 31, 2021

The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:


	For the Three Months Ended
	December 31		September 30		June 30		March 31
2021
Total revenue	$	248,358	$	222,471	$	222,057	$	215,071
Total operating expenses	260,572		229,052		229,728		231,016
Net loss from continuing operations	3,053		(13,040)		(9,107)		(11,190)
Net income (loss) from discontinued operations, net of tax	(8,700)		—		—		1,383
Net loss attributable to common shareholders of Evolent Health, Inc.	(5,647)		(13,040)		(9,107)		(9,807)

Income (loss) per common share
Basic and diluted
Continuing operations	$	0.03	$	(0.15)	$	(0.11)	$	(0.13)
Discontinued operations	(0.09)		—		—		0.01

2020
Total revenue	$	246,536	$	239,572	$	217,299	$	221,232
Total operating expenses	246,804		256,020		443,128		246,323
Net loss from continuing operations	(10,637)		(37,035)		(202,013)		(78,487)
Net loss from discontinued operations, net of tax	(3,166)		(1,135)		(1,508)		(265)
Net income (loss) attributable to non-controlling interests	822		(822)		—		—
Net loss attributable to common shareholders of Evolent Health, Inc.	(14,625)		(37,348)		(203,521)		(78,752)

Loss per common share
Basic and diluted
Continuing operations	$	(0.13)	$	(0.43)	$	(2.37)	$	(0.93)
Discontinued operations	(0.04)		(0.01)		(0.01)		—